Rekah Pharmaceutical Industry Ltd. (TLV:REKA)
Israel · Delayed Price · Currency is ILS · Price in ILA 1,120.00
-2.00 (-0.18%)
Sep 29, 2026, 11:04 AM IDT
TLV:REKA Ratios and Metrics
Market cap in millions ILS. Fiscal year is January - December.
Millions ILS. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 28, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 128 | 125 | 151 | 169 | 176 | 266 | |
Market Cap Growth | 1.54% | -17.43% | -10.35% | -3.96% | -33.89% | -13.13% |
Enterprise Value | 243 | 254 | 295 | 338 | 321 | 420 |
Last Close Price | 11.22 | 10.94 | 13.25 | 14.78 | 15.39 | 22.40 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 28, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | - | - | 24.37 | - | - | 40.12 |
PS Ratio | 0.42 | 0.42 | 0.47 | 0.52 | 0.60 | 1.01 |
PB Ratio | 0.91 | 0.87 | 0.93 | 1.08 | 1.08 | 1.54 |
P/TBV Ratio | 1.49 | 1.42 | 1.50 | 1.90 | 1.39 | 1.90 |
P/FCF Ratio | 5.56 | 21.08 | 8.47 | 10.01 | 5.48 | 34.59 |
P/OCF Ratio | 4.57 | 9.64 | 5.70 | 5.95 | 4.50 | 12.55 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 28, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 0.80 | 0.85 | 0.92 | 1.05 | 1.10 | 1.59 |
EV/EBITDA Ratio | 10.61 | 16.58 | 11.72 | 10.31 | 7.87 | 11.73 |
EV/EBIT Ratio | - | - | - | 116.43 | 24.20 | 32.49 |
EV/FCF Ratio | 10.56 | 42.96 | 16.53 | 20.07 | 10.00 | 54.61 |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 28, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.87 | 0.92 | 0.83 | 1.18 | 1.02 | 0.96 |
Debt / EBITDA Ratio | 5.29 | 5.67 | 5.33 | 5.60 | 4.07 | 4.64 |
Debt / FCF Ratio | 5.32 | 22.35 | 7.52 | 10.89 | 5.17 | 21.59 |
Net Debt / Equity Ratio | 0.82 | 0.89 | 0.79 | 1.06 | 0.90 | 0.85 |
Net Debt / EBITDA Ratio | 7.62 | 8.34 | 5.05 | 5.01 | 3.57 | 4.12 |
Net Debt / FCF Ratio | 5.00 | 21.61 | 7.12 | 9.74 | 4.53 | 19.16 |
Asset Turnover | 0.72 | 0.69 | 0.69 | 0.69 | 0.66 | 0.62 |
Inventory Turnover | 2.48 | 2.67 | 2.79 | 2.56 | 2.35 | 2.12 |
Quick Ratio | 0.86 | 0.92 | 0.90 | 1.01 | 1.06 | 1.30 |
Current Ratio | 1.41 | 1.53 | 1.45 | 1.75 | 1.75 | 2.25 |
Return on Equity (ROE) | -10.69% | -11.81% | 3.91% | -4.35% | -1.22% | 3.91% |
Return on Assets (ROA) | -1.00% | -1.04% | -0.98% | 0.39% | 1.87% | 1.88% |
Return on Invested Capital (ROIC) | -2.60% | -2.58% | -1.89% | 0.93% | -24.16% | 3.60% |
Return on Capital Employed (ROCE) | -2.70% | -2.70% | -2.50% | 0.90% | 4.30% | 3.80% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 28, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | -12.34% | -14.47% | 4.10% | -4.10% | -1.16% | 2.49% |
FCF Yield | 17.98% | 4.74% | 11.80% | 9.99% | 18.25% | 2.89% |
Dividend Yield | - | - | - | - | - | 3.87% |
Total Shareholder Return | 1.54% | - | - | - | - | 3.87% |